Open AccessAssociation of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b
Author(s) -
Kathryn C. Fitzgerald,
Kassandra L. Munger,
Karl Köchert,
Barry G.W. Arnason,
Gıancarlo Comı,
Stuart D. Cook,
Douglas S. Goodin,
Massimo Filippi,
Hans-Peter Hartung,
Douglas Jeffery,
Paul O’Connor,
Gustavo Cruz,
Rupert Sandbrink,
Ludwig Kappos,
Christoph Pohl,
Alberto Ascherio
Publication year - 2015
Publication title -
jama neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.298
H-Index - 231
eISSN - 2168-6157
pISSN - 2168-6149
DOI - 10.1001/jamaneurol.2015.2742
Subject(s) - medicine , multiple sclerosis , vitamin d and neurology , interferon beta 1a , interferon beta 1b , prospective cohort study , glatiramer acetate , clinical trial , randomized controlled trial , magnetic resonance imaging , clinically isolated syndrome , gastroenterology , disease , immunology , interferon beta , radiology
Low serum 25-hydroxyvitamin D (25[OH]D) levels are associated with an increased risk of multiple sclerosis (MS) as well as with increased disease activity and rate of progression in clinically isolated syndromes and early MS.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom